Future of neuroprotection in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 8, Issue 2, 2001, Pages 139-145

  Naoi, Makoto ^a   Maruyama, Wakako ^b  

^a Institute of Applied Biochemistry   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Anti apoptotic drugs; Apoptosis; Caspase 3; Glyceraldehyde 3 phosphate dehydrogenase; Mitochondrial membrane potential; Propargylamines

Indexed keywords

3 (2 HEPTYLAMINO)PROPIONIC ACID; AMINOINDANE; ANTIOXIDANT; APOMORPHINE; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKING AGENT; CASPASE 3; CASPASE INHIBITOR; DESMETHYLSELEGILINE; DOPAMINE RECEPTOR STIMULATING AGENT; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FLAVANOID; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INDAN DERIVATIVE; IRON CHELATING AGENT; N 2 HEPTYL N METHYLPROPARGYLAMINE; N 2 HEPTYLPROPARGYLAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; OXIDOPAMINE; PEROXYNITRITE; PROPARGYLAMINE DERIVATIVE; PROPIONIC ACID DERIVATIVE; QUINPIROLE; RASAGILINE; SALICYLIC ACID DERIVATIVE; SALSOLINOL; SCAVENGER; SELEGILINE; UNCLASSIFIED DRUG;

APOPTOSIS; CONFERENCE PAPER; DNA DAMAGE; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NEUROBLASTOMA CELL; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

APOPTOSIS; HUMANS; MOLSIDOMINE; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NITRIC OXIDE DONORS; OXIDOPAMINE; PARKINSON DISEASE; PROPYLAMINES; SALSOLINE ALKALOIDS; SELEGILINE; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED;

EID: 0034899354     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(01)00028-1     Document Type: Conference Paper

References (31)

1. Mapping of a gene for Parkinson's disease to chromosome 4q21-q2
2. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
3. Oxidative stress: A role in the pathogenesis of Parkinson's disease
4. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds
5. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors
6. A multicenter controlled clinical trial in early Parkinson's disease
7. Cell death mechanisms in Parkinson's disease
8. Apoptosis in the pathogenesis and treatment of disease
9. Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism
10. Deprenyl protects dopaminergic neurons from neurotoxic effects of 1-methyl-4-phenylpyridiniun ion
11. An endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells
12. (-)Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide
13. N-Methyl(R)salsolinol, a dopamine neurotoxin, in Parkinson's disease
14. Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl(R)salsolinol induced parkinsonism in rat: Biochemical, pathological and behavioral studies
15. Neurotoxin induced apoptosis in dopamine neurons: Protection by N-propargylamine-1-(R)- and (S)-aminoindan, rasagiline and TV1022
16. Apoptosis induced by endogenous neurotoxin, N-methyl(R)salsolinol, is mediated by activation of caspase 3
17. Enantio-specific induction of apoptosis by an endogenous neurotoxin. N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: Suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine
18. Pharmacology of rasagiline (N-propargyl-1R-aminoindan)
19. Alkaloids in mammalian tissues. 2. Synthesis of (+) and (-)-1-substituted-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines
20. R-Enantiomers of N-propargyl-aminoindan compounds. Their preparation and pharmaceutical composition containing them
21. Aliphatic propargylamines: Potent, selective, irreversible monoamine oxidase B inhibitors
22. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl
23. Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity
24. Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO B
25. Effect of ethylcholine mustard aziridinium (AF64A) and on monoamine oxidase-B-inhibitor L-deprenyl on the morphology of rat hippocampus
26. + in vivo
27. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration
28. (-)Deprenyl induces activities of both superoxide dismutase and catalase but not glutathione peroxidase in the striatum of young male rats
29. R-Deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium
30. Loss of mitochondrial membrane potential is dependent on the apoptotic program activated: Prevention by R-HMP
31. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear translocation of glyceraldehydes-3-phosphate dehydrogenase induced by an endogenous dopaminergic, N-methyl(R)salsolinol